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Biomarkers for pulmonary manifestations in systemic lupus erythematosus (SLE) are missing.
Plasma samples of nine SLE patients with known pulmonary involvement (SLEpulm) and nine
SLE patients without pulmonary involvement (SLE) were tested by multiplex microarray
analysis for various cyto- and chemokines. Significantly decreased lung function paramters
for forced vital capacity (FVC), total lung capacity (TLC), diffusion capacity for carbon
monoxide (DLCO) and diffusion of CO corrected on lung volume (KLCO) were observed in
SLEpulm as compared to SLE patients. CC chemokine ligand 21 (CCL21) and interferon
gamma-induced protein 10 (IP-10) levels were significantly higher in SLEpulm, than in patients
without pulmonary manifestations. CCL21 correlated negatively with DLCO (r¼0.73;
p< 0.01) and KLCO (r¼0.62; p< 0.01), while IP-10 with FVC and forced expiratory
volume one second. Receiver Operating Characteristics (ROC) analysis confirmed high sen-
sitivity and specificity for the separation of SLE patients with and without pulmonary involve-
ment for the chemokines CCL21 (Area Under Curve (AUC): 0.85; sensitivity%: 88.90;
specificity%: 75.00; p< 0.01) and IP-10 (AUC: 0.82; sensitivity%: 66.67, specificity%: 100;
p< 0.01). Pleuropulmonary manifestations in SLE patients associated with lung functional
and DLCO/KLCO changes and were associated with significant increase in CCL21 and IP-10.
These chemokines might serve as potential biomarkers of lung involvement in SLE
patients. Lupus (2016) 0, 1–8.
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Introduction
Systemic lupus erythematosus (SLE) is a sys-
temic autoimmune disease that can aﬀect
almost any organ system. The disease is charac-
terised by an autoantibody response to nuclear
and cytoplasmic antigens.1 SLE predominantly
aﬀects females with onset during child-bearing
age, with a female–male ratio of 9:1 and a higher
prevalence in Hispanics, African-Americans and
Afro-Caribbeans as compared to the Caucasian
population.2,3 Its presentation and course are
highly variable, ranging from inactive to
fulminant.4
Involvement of the respiratory tract is more fre-
quent in SLE patients, as previously assumed and
also conﬁrmed in our previous study.5 The preva-
lence ranges from 4.9 to 50% in the adult popula-
tion, while it is 5–67% in juvenile SLE according to
previous studies, depending upon whether only
symptomatic patients or detailed pulmonary exam-
inations are included.6–8 The disease might present
with the ﬁrst signs of pulmonary symptoms in
about 4–5% of patients and lungs are frequently
involved during the disease course.9 Depending
on the aﬀected area, pulmonary manifestations
include pleuritis, interstitial lung disease (ILD),
airway disease, vascular or musculoskeletal
involvement.10 Moreover, some other conditions,
such as pulmonary embolism, complement-
mediated leukoaggregation, infections or the life
threatening alveolar haemorrhage can accompany
the disorder.11
The role of inﬂammatory cyto- and chemokines
is well known in the pathogenesis of SLE, however
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the results are controversial and suggest that com-
binations of diﬀerent biomarker measurements
could be useful to follow up disease activity or
organ involvement.12 In terms of lung involvement
only a few studies are available, suggesting that
some of these markers can be elevated in blood
and exhaled breath condensate of SLE patients
with pulmonary manifestations.13,14 Previous stu-
dies reported interleukin (IL)-6, IL-8, interferon-g
(INF-g) and tumor necrosis factor-a (TNF-a) as
possible markers for pulmonary manifestation in
SLE patients.13,15 However, these markers are not
speciﬁc enough to identify the pulmonary manifest-
ations, as their levels are elevated in many patho-
physiological conditions.
Despite the potentially high prevalence of lung
complications in SLE, only a limited number of
studies assessed risk factors that might predict pul-
monary manifestations or biomarkers associated
with lung involvement. Nevertheless, no previous
studies speciﬁcally investigated the possible role of
cyto- and chemokines in SLE patients with and
without lung manifestations. Therefore, we chose
10 possible cyto- and chemokines based on the lit-
erature background of their possible role in the
pathogenesis of SLE or diseases of the lung. Our
aim was to test and identify potential biomarkers
for pulmonary manifestations and to examine their
relationship with clinical parameters in this rare,
but high risk, group of SLE patients.
Methods
Patient recruitment
Healthy control subjects (n¼ 9) were all volunteers.
Nine SLE patients with known lung manifestations
(SLEpulm) and nine SLE patients without lung
involvement (SLE) were enrolled into the study.
SLE patients were recruited consecutively at the
outpatient clinic of the Department of
Pulmonology, Semmelweis University, having
been referred to our clinic for pleuropulmonary
involvement screening by the National
Department of Rheumatology and Physiotherapy.
All patients fulﬁlled the American College of
Rheumatology (ACR) criteria for the classiﬁcation
of SLE.16 Patients with infections six weeks prior to
the study were excluded. All cases were of
Caucasian ethnic origin.
Written informed consent was obtained from all
subjects, and our study was reviewed and approved
by the Ethical Committee of the National Institute
of Rheumatology and Physiotherapy (reference
number: ad.223/2014/EKU). The study adhered
to the tenets of the most recent revision of the
Declaration of Helsinki.
Study design
Venous blood was collected into EDTA tubes from
all subjects, centrifuged at 1500 r/min at 4C within
two hours for routine haematological analysis and
the remaining sample was stored at 80C until
cytokine and chemokine measurements. Organ
manifestations and actual medications were rec-
orded from medical ﬁles. Patients were asked
about their respiratory symptoms, underwent phys-
ical examination, chest X-ray, electrocardiography
and routine laboratory analysis. Arterialised capil-
lary blood gases, pH and bicarbonate levels were
analysed in all patients at rest in room air
(Roche Cobas b 221 Blood Gas system, Roche
Diagnostics Corporation, USA).
Spirometry [Forced vital capacity (FVC), forced
expiratory volume 1 (FEV1), FEV1/ FVC, forced
expiratory ﬂow between 25% and 75% of FVC
(FEF25-75), total lung capacity (TLC), residual
volume (RV), thoracic gas volume (TGV) and
airway resistance (Raw)] was measured by means
of electronic spirometer (PDD-301/s, Piston,
Budapest, Hungary) according to the American
Thoracic Society guidelines.17 Three technically
acceptable manoeuvres were performed, and the
best of them was evaluated. Diﬀusion capacity for
carbon monoxide (CO) (DLCO) and diﬀusion of
CO corrected on lung volume (KLCO) were mea-
sured with single breath method (PDD-301/s,
Piston, Budapest, Hungary). Pulmonary function
variables were expressed as a percentage of pre-
dicted values.
Cytokine antibody array and quantification
Custom made human Cytokine Antibody Array
Kits (RayBiotech Inc., Norcross, GA, USA) were
used to determine plasma cyto- and chemokine
levels. Microarray analysis was carried out accord-
ing to the recommendations of the array manufac-
turer. The following factors were measured in
parallel on a single array per patient: 4BB-1; inter-
feron gamma-induced protein 10 (IP-10); interleu-
kin-12, p70 (IL12p70); interleukin-17 (IL-17); CC
chemokine ligand 14a (CCL14); CC chemokine
ligand 21 (CCL21); CC chemokine ligand 28
(CCL28); monocyte chemotactic protein 1 (MCP-
1); monocyte chemotactic protein 4 (MCP-4);
interferon–inducible T cell alpha chemoattractant
(I-TAC). Signal intensities were recorded and
sorted using a chemiluminescence imaging system
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(Syngene Chemigenius 2 and GeneTools, Synoptics
Ltd. Cambridge, UK). Background corrected raw
intensities were used for analysis.
Statistical analysis
Statistical analyses were performed applying the
following software: Graph Pad Prism software 5.0
(GraphPad Software, La Jolla, CA, USA). The
normality distribution of the data was assessed by
the Kolmogorov–Smirnoﬀ test. Clinical data
between SLE patient groups and controls were ana-
lyzed by one-way ANOVA test if the data showed
normal distribution and Kruskal-Wallis U test fol-
lowed by Dunn’s post hoc test if the data were not
normally distributed. The relationship between
clinical parameters and microassay results was
determined with Spearman rank correlation when
the data showed normal distribution and Pearson
rank correlation with not normally distributed
data. Area Under Curve (AUC) values of
Receiver Operating Characteristics (ROC) curves
were calculated using standard methods and data
are presented as AUC ROC (95% CI). For all
statistical analyses p< 0.05 was considered statistic-
ally signiﬁcant. Unless otherwise speciﬁed, data are
reported as mean SEM for continuous variables
and as number (percent) for categorical variables.
Results
Clinical characteristics
The study had a cross sectional design. Baseline
patient characteristics are summarised in Table 1.
There was no statistically signiﬁcant diﬀerence in
mean age (50.48 2.69 versus 38.23 5.46 years;
p> 0.05) between the SLE and SLEpulm groups.
Patients without lung manifestations had higher
body mass index (BMI) than SLEpulm (27.29
2.06 versus 20.64 1.52 kg/m2; p< 0.01). Forty-
four percent (4 out of 9) of SLEpulm and SLE
patients were smokers. Pack/year exposures were
comparable in the two groups. Eighty-eight percent
of the SLEpulm patients were on corticosteroid ther-
apy and had higher doses than the 44% of SLE
patients, as summarised in Table 1.
Table 1 Patient characteristics of systemic lupus erythematosus patients with and without lung manifestations
SLE patients without
lung manifestations
SLE patients with
lung manifestations p-values
Number of patients (n) 9 9 —
Female/male 9/0 7/2 —
Age 50.48 2.69 38.23 5.46 0.0615
mean [range] [33–60] [17–65]
BMI (kg/m2) 27.29 2.06 20.64 1.52 0.0142
Smoker n (%) 4 (44) 4 (44) —
Pulmonary symptoms
Cough n (%) 4 (44) 5 (55) —
Dyspnea n (%) 6 (67) 4 (44)
Chest pain n (%) 3 (33) 2 (22)
Methylprednisolone (all), n (%) 4 (44) 8 (88) —
4mg/day, n 2 2
8mg/day, n 2 4
16mg/day, n 0 2
ACR criteria
Malar rash n (%) 4 (44) 4 (44) —
CDLE n (%) 0 (0) 1 (11)
Photosensitivity n (%) 8 (88) 3 (33)
Mucosal lesions n (%) 3 (33) 0 (0)
Arthritis n (%) 7 (77) 8 (88)
Serositis n (%) 3 (33) 5 (55)
Kidney n (%) 2 (22) 3 (33)
CNS n (%) 3 (33) 3 (33)
Hematological n (%) 6 (66) 5 (55)
Immunological n (%) 5 (55) 6 (66)
ANA positivity n (%) 8 (88) 9 (100)
Data expressed as mean SEM if not stated otherwise.
BMI¼body mass index; ACR¼American College of Rheumatology; ANA¼ antinuclear antibody; CDLE¼ chronic discoid lupus
erythematosus; CNS¼ central nervous system.
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Pulmonary symptoms did not diﬀer signiﬁcantly
in SLEpulm patients as compared to SLE patients.
In both groups, dyspnea and cough were the lead-
ing respiratory complaints. Types of pulmonary
involvement(s) of each individual in the SLEpulm
group are listed in Table 2. Interstitial lung disease
(ILD) and small airway involvement were the most
common lung involvements, while one patient had
shrinking lung syndrome (SLS) without diﬀusion
capacity changes. Moreover, only one patient had
bronchiectasis and one other was diagnosed with
concomitant emphysema.
The results of lung function and diﬀusion par-
ameters for the respective SLE groups are given in
Table 3. The mean values of lung function param-
eters were in the normal range in SLE patients,
however FVC (99.00 2.75 versus 79.89 7.26%
predicted; p¼ 0.02) and TLC (93.22 3.40 versus
76.89 3.37% predicted; p< 0.01) were decreased
in the SLEpulm patients. In addition, decreased
values of diﬀusion parameters were observed in
SLEpulm patients including DLCO (90.56 6.79
versus 60.75 5.18% predicted; p< 0.01) and
KLCO (72.78 4.71 versus 60.25 3.69% pre-
dicted; p¼ 0.06). Blood gas parameters did not
diﬀer in the study groups.
Comparison of chemo- and cytokine levels between
SLEpulm and SLE patients
In several plasma samples the levels of 4BB-1,
IL12p70, IL-17, CCL28, MCP-4 and I-TAC were
below the detection limit of the array, therefore
only data obtained for the remaining factors,
CCL21, IP-10, MCP-1 and CCL14, were used in
the statistical analysis.
As presented in Figure 1, the chemiluminescent
intensity of CCL21 was signiﬁcantly higher in
SLEpulm than in patients without lung involvement;
however, no signiﬁcant diﬀerence to the control
group has been identiﬁed (4949 1481 versus
1272 236.1 versus 1581 382.1 U; p< 0.05;
Figure 1(a)). A signiﬁcantly increased chemilumines-
cent intensity was detected for circulating IP-10 in the
SLEpulm group as compared to SLE patients and
healthy volunteers (5923 1278 versus 5759 926
versus 10,762 1584 U; p< 0.05; respectively;
Figure 1(b)). In the case of MCP-1, the diﬀerence
between the SLE study groups has not reached stat-
istical signiﬁcance; nevertheless, a tendency to an ele-
vated level in the SLEpulm group was observed.
However, in comparison with the control group,
the SLEpulm patients showed a higher level of
MCP-1 (20337 8809 versus 15667 1611 versus
54273 19319 U; p< 0.05; S1/A). CCL14 levels did
not diﬀer between the study groups (275613 36125
versus 232092 25276 versus 320154 50029 U;
p> 0.05; respectively; Figure S1(b)).
Relationship of chemo- and cytokine levels to lung
function parameters in all SLE patients
No association was found between lung function
parameters and CCL21 in SLE patients. In con-
trast, signiﬁcant association was demonstrated
regarding lung function parameters FVC and
FEV1 and IP-10; MCP-1; CCL14, as shown in
Figure S2/A–F. Moreover, IP-10 showed
correlation with TLC (r¼0.59; p< 0.01; no
ﬁgure added) and Raw (r¼ 0.55; p¼ 0.01; no
ﬁgure added). In addition, CCL14 correlated nega-
tively with FEF25–75 (r¼0.69; p< 0.01; no ﬁgure
added), but showed positive correlations with TGV
(r¼ 0.49; p¼ 0.03; no ﬁgure added), RV (r¼ 0.54;
p¼ 0.02; no ﬁgure added) and RV/TLC (r¼ 0.64;
p< 0.01; no ﬁgure added).
Table 2 Appearance of lung involvement in systemic lupus erythematosus patients and immunosuppressive therapy used
Patient ID
number Gender Agea
Lung function
abnormality
Diffusion
capacityb
Lung
involvementc
Systemic
immunosuppressive therapyd
SLE 1 Female 59 Restrictive ## ILDþ bronchiectasia MP
SLE 2 Female 41 Mixed ## ILDþ SAI MP
SLE 3 Female 23 Restrictive — SLS MP, AZA
SLE 4 Female 40 Obstructive # SAI MP
SLE 5 Male 65 — ## ILDþ emphysema —
SLE 6 Male 40 Mixed ## ILDþ SAI MP
SLE 7 Female 17 Restrictive ## ILD MP, CSA
SLE 8 Female 36 Restrictive ## ILD MP, AZA
SLE 9 Female 19 Restrictive ## ILD MP
aMean age at the time of the recruitment into the study.
b# ¼ decreased; ## ¼ severely decreased.
cILD¼ interstitial lung disease; SAI¼ small airway involvement; SLS¼ shrinking lung syndrome.
dMP¼Methylprednisolone; AZA¼Azathioprine; CSA¼Cyclosporine A; MTX¼Methotrexate.
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Relationship of chemo- and cytokine levels to
diffusion parameters in all SLE patients
Correlation analyses revealed positive correlation
between the chemiluminescent intensity of CCL21
and diﬀusion parameters, including DLCO (r¼
0.73; p< 0.01; Figure S3(a)) and KLCO (r¼0.62;
p< 0.01; Figure S3(b)). However, IP-10; MCP-1 and
CCL14 did not show correlation with diﬀusion par-
ameters in SLE patients (all p-values> 0.05).
ROC analysis of CCL21 and IP-10 values in SLE
patients with and without lung manifestations
The potential value of CCL21 and IP-10 in the
identiﬁcation of lung involvement in SLE patients
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Figure 1 Comparison of CCL21 (a) and IP-10 (b) in healthy volunteers and in systemic lupus erythematosus patients with
(SLEpulm) and without pulmonary (SLE) involvement. ((a): SLE versus SLEpulm, p< 0.05; SLEpulm versus control and SLE,
p< 0.05, respectively).
Table 3 Lung function, diffusion capacity and blood gas parameters of patients with and without lung
manifestations
Clinical parameters
SLE patients without
lung manifestations
SLE patients with
lung manifestations p-values
Lung function parameters
FVC (% pred) 99.00 2.75 79.89 7.26 0.024
FEV1 (% pred) 93.11 3.52 77.00 7.69 0.075
FEV1/FVC (% pred) 101.10 1.98 96.78 5.82 0.490
FEF25-75 (% pred) 80.67 9.00 65.22 11.18 0.297
TLC (% pred) 93.22 3.40 76.89 3.37 0.003
TGV (% pred) 124.60 4.74 116.30 7.50 0.368
RV (% pred) 95.33 6.00 89.22 12.66 0.668
RV/TLC (% pred) 100.00 5.05 111.00 14.89 0.756
Raw (kP*s/L) 0.147 0.022 0.227 0.046 0.139
Diffusion parameters
DLco (ml/min/mmHg) 22.81 2.06 16.16 2.13 0.041
DLco (%) 90.56 6.79 60.75 5.18 0.003
KLco (ml/min/mmHg) 1.487 0.10 1.231 0.09 0.082
KLco (%) 72.78 4.71 60.25 3.69 0.055
Blood gas parameters
pH 7.449 0.010 7.456 0.007 0.551
pO2 (Hgmm) 83.37 2.65 91.86 4.45 0.138
pCO2 (Hgmm) 32.20 2.06 30.63 1.46 0.537
HCO3
- (mmol/l) 22.44 1.38 22.13 0.77 0.839
Blood chart results
CRP (mg/L) 4.62 1.10 11.24 4.35 0.385
WBC (G/L) 7.44 1.44 9.18 1.16 0.362
Neutrophil (%) 62.99 3.64 71.86 4.72 0.159
Thrombocyte (G/L) 269.40 26.10 273.90 38.21 0.923
Lymphocyte (%) 26.56 3.07 20.10 4.21 0.236
Data expressed as mean SEM if not stated otherwise. Abbreviations are listed in the main text.
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was tested using ROC analysis comparing SLE
patients without and with pulmonary manifest-
ations. Statistical signiﬁcance was proved for both
CCL21 and IP-10.
ROC analysis of CCL21 values in the SLE
patient groups with and without pulmonary
involvement yielded an AUC of 0.847 (95% CI:
0.593–0.972) with a 1664.39 U cut-oﬀ value of
CCL21 to discriminate between patients with and
without pulmonary manifestation (sensitivity%:
88.90; speciﬁcity%: 75.00; p< 0.01; Figure S4(a)).
The area under the ROC curve for identiﬁcation
of pulmonary involvement in the case of IP-10 was
0.815 (95% CI: 0.565–0.955). The cut-oﬀ value of
IP-10 to discriminate between SLEpulm and SLE
without pulmonary manifestations was 8971.62 U
(sensitivity%: 66.67, speciﬁcity%: 100; p< 0.01;
Figure S4(b)).
Discussion
The search for lupus biomarkers has emerged enor-
mously in the last few years; however, biomarkers
for detection of the rare but severe lung involve-
ment are not yet available.18
Our results are the ﬁrst to describe chemokines in
peripheral blood as possible biomarkers for lung
involvement in SLE patients. CCL21 and IP-10
showed signiﬁcant changes according to lung
involvement in this autoimmune disorder. CCL21
demonstrated strong correlation with decline in dif-
fusion parameters, whereas IP-10 was associated
with decreased static lung volumes and lung func-
tion parameters indicating airway involvement.
Moreover, based on our ROC analysis results,
these biomarkers could be promising for the diﬀer-
entiation of pulmonary involvement in SLE
patients. MCP-1 did not diﬀer signiﬁcantly in
study groups; however, the correlation results are
indicative for further studies about this chemokine
as well.
The age of the patients did not diﬀer signiﬁcantly
between our study groups, but it tended to be
higher in SLE patients. The age of the individual
patients ranged in the same way within the two
groups, except for three younger patients in the
SLEpulm group (as shown in Table 2). Apparently,
it is diﬃcult to discuss the topic due to the known
disturbances of the immune system in this disease;
however, it might not have inﬂuence on our results
based on the available literature suggesting that
age-associated changes in cytokine production are
not consistent.19
The role of chemokines and cytokines in SLE is
extensively investigated due to the known disturb-
ances of the immune system in this disease.
Dysregulated activation of both T and B lympho-
cytes and subsequent polyclonal activation of cir-
culating B lymphocytes were shown in previous
studies.20 These abnormalities lead to the produc-
tion of a large amount of autoreactive antibodies
and the formation of immune complexes respon-
sible for tissue and organ damage.21 Chemokines
are important for leukocyte recruitment into
inﬂamed tissues, initiation of T cell immune
response and regulation of diﬀerential recruitment
of T helper (Th)1 and Th2 lymphocytes.22,23
Chemokines are divided into four subfamilies
depending on the position of the conserved cysteine
residues (CXC, CC, C and CX3C).24 There has
been growing evidence showing that inﬁltration of
T lymphocytes and other leukocytes into the
inﬂamed tissues might play a critical role in organ
involvement in SLE.25
CCL21 is a chemotactic chemokine that binds to
and activates its receptor – CCR7 – and induces
cellular activation and migration. CCR7 is highly
expressed on T-lymphocytes and activated den-
dritic cells, where it has an important role in the
navigation of these cells into lymphoid tissues.26 On
the other hand, CCL21 and CCR7 have been iden-
tiﬁed as crucial players in the progression of lung
ﬁbrosis.27 CCR7 is expressed on lung ﬁbroblasts
and is important in their activation, survival and
proliferation.28 A study by Pierce and colleagues
demonstrated that CCL21 modulates the func-
tional properties of idiopathic pulmonary ﬁbrosis/
usual interstitial pneumonia ﬁbroblasts.29 The role
of CCL21 in SLE was not widely investigated; how-
ever, its close correlation with diﬀusion parameters
DLCO and KLCO in our study suggests potential
functions in interstitial lung involvement in SLE
patients.
The chemokine receptor IP-10 was found signiﬁ-
cantly up-regulated in our SLEpulm cohort. IP-10 is
secreted by several cell types, including T lympho-
cytes, neutrophils, monocytes, endothelial cells or
ﬁbroblasts.30 It is chemotactic for activated Th1
cells and together with IL-6 induces plasma cell dif-
ferentiation.31 Recruited Th1 lymphocytes may be
responsible for enhanced IFN-g and TNF-a pro-
duction, which in turn stimulates IP-10 secretion
from a variety of cells, leading to an ampliﬁcation
feedback loop. The importance of these substances
was demonstrated as elevated levels of IFN-g and
TNF-a were found in SLE patients with pulmonary
involvement.32,13
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IP-10 level was elevated in the serum, urine and
cerebrospinal ﬂuid of SLE patients depending on
the level of disease activity.33,34 Our data also sug-
gest that higher IP-10 values are associated with
more pronounced respiratory involvement; how-
ever, data on disease activity score were not avail-
able. CC chemokines are also important in
inﬂammatory cell recruitment into the lungs in idio-
pathic interstitial pneumonias.35,36 Although blood
levels of IP-10 have not been widely investigated in
patients with lung ﬁbrosis, some studies suggest
their role in other ﬁbrotic diseases (e.g. liver ﬁbro-
sis), where elevated levels of IP-10 were detected.37
Antonelli and colleagues demonstrated that high
IP-10 values are associated with more severe clin-
ical phenotype and with the presence of lung ﬁbro-
sis in systemic sclerosis patients.38
Markers of inﬂammatory activity are important
for the assessment and management of chronic
airway diseases with chronic inﬂammation and
loss of lung volume, like chronic obstructive pul-
monary disease (COPD).39 IP-10 was elevated in
exacerbated COPD patients’ sputum and another
study showed negative correlation with FVC.40,41
Moreover, the marker increased from baseline in
human rhinovirus induced exacerbations and cor-
related with sputum viral load in COPD subjects.42
IP-10 is supposed to have a central role in Th1
mediated diseases.43 Consistent with that, our
research group has previously described that SLE
patients with pulmonary involvement had signiﬁ-
cant changes in peripheral Th1/Th2 cells.5 The ﬁnd-
ings in COPD patients and our lung function
(FEV1 and FVC) correlation results suggest that
IP-10 in SLE patients with lung involvement can
be an indicator of inﬂammatory activation in the
airways and loss of lung function in SLE patients.
MCP-1 also showed correlation with lung func-
tion parameters (FVC(%) and FEV1(%)) and
showed a tendency for up-regulation in patients
with pulmonary involvement. Many studies have
found correlation between disease activity and
MCP-1, mostly in urinary samples indicating the
severity of lupus nephritis.44 Moreover, it has
been described as a potential biomarker in the pre-
diction of future ﬂare of SLE.45 However, to our
knowledge, its role in lung involvement has not
been investigated. Like IP-10, MCP-1 is also a
proinﬂammatory cytokine which can play a role
in the inﬂammatory activation of the airways, con-
tributing to the development of respiratory symp-
toms. On the other hand, CCL14 also correlated
negatively with lung function parameters
(FVC(%) and FEV1(%)); however, it showed no
diﬀerence in the two study groups. It would be
important to investigate these biomarkers on a
larger study cohort to establish them as a possible
diagnostic marker of lung involvement in SLE.
Conclusions
Lung involvement in SLE is rare, but often severely
inﬂuences patient outcome. Our results suggest that
IP-10 and CCL21 might be important biomarkers
in the diﬀerentiation of SLE patients with and with-
out pulmonary involvement. Our patients showed
similar respiratory symptoms, and only lung func-
tion was signiﬁcantly diﬀerent between the groups.
As these patients are prone to pulmonary symp-
toms, it is of major interest if pulmonary changes
that cannot be measured clinically could be pre-
dicted using IP-10 and/or CCL21. CCL21 seems
to be mainly a marker for interstitial lung involve-
ment, while IP-10 is more a marker for lung volume
and airway centred lung changes of SLE. The
importance of our work is in identifying signiﬁcant
and important blood biomarkers for possible use as
an easy test in clinical praxis for this rare condition;
however, our results need to be conﬁrmed on a
larger study population.
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